Barney S Graham

US Patent:

7132453, Nov 7, 2006

Filed:

Mar 14, 2003

Appl. No.:

10/389295

Inventors:

Koichi Hashimoto - Kohriyama Fukushima, JP
Barney S. Graham - Rockville MD, US

Assignee:

Vanderbilt University - Nashville TN

International Classification:

A01N 37/08
A01N 53/00
A61K 31/19
A61K 31/557

US Classification:

514573, 554117, 549422

Abstract:

The present invention discloses methods and a kit for treating a respiratory syncytial virus infection. The method comprises providing an infection modulator, and administering a therapeutically effective amount of the infection modulator, wherein the respiratory syncytial virus infection is suppressed or precluded. The kit for suppressing a respiratory syncytial virus infection comprises an infection modulator, an applicator, and a set of instructions.

US Patent:

20020142940, Oct 3, 2002

Filed:

Oct 16, 2001

Appl. No.:

09/981682

Inventors:

Barney Graham - Rockville MD, US
Tara Gower - Nashville TN, US
Manoj Pastey - Silver Spring MD, US

International Classification:

A61K031/00

US Classification:

514/001000

Abstract:

Applicants provide methods of inhibiting viral infections, and treating an infected individual with AIDS, respiratory syncytial virus infection, parainfluenza virus infection, and other viral infections. Inhibitors of Rho isoprenylation are used to inhibit Rho cell surface attachment, thereby inhibiting the use, by viruses, of Rho as a receptor for infection of susceptible cells. Isoprenylation inhibitors include inhibitors specific for the enzymes farnesyltransferase and geranylgeranyltranferase, as well as inhibitors of general cholesterol biosynthesis, such as HMG-CoA reductase inhibitors.

US Patent:

20050226889, Oct 13, 2005

Filed:

Nov 9, 2004

Appl. No.:

10/984377

Inventors:

Barney Graham - Rockville MD, US
Manoj Patsey - Corvallis OR, US

International Classification:

A61K039/12
A61K039/155

US Classification:

424186100

Abstract:

Isolated peptides, peptidomimetics, and antibodies which bind to the viral fusion protein binding domain of the RhoA protein or the RhoA binding domain of a viral fusion protein are useful for inhibiting infection in susceptible cells, in vitro and in vivo. Among these viruses are the Paramyxovirus respiratory syncytial virus (RSV) and the Lentivirus human immunodeficiency virus (HIV).

US Patent:

20100247621, Sep 30, 2010

Filed:

Nov 30, 2007

Appl. No.:

12/517194

Inventors:

Barney S. Graham - Rockville MD, US
Teresa R. Johnson - Gaithersburg MD, US

Assignee:

Government of the US, as represented by the Secretary, Department of Health and Human Services - Rockville MD

International Classification:

A61K 9/127
C07H 21/04
C12N 15/74
C07H 21/02
C12N 5/071
A61K 39/00
A61K 31/7105
A61K 31/711
A61K 39/12
A61K 39/155
G01N 33/53
A61K 39/245
A61K 39/145
A61K 39/17
A61K 39/275
A61K 39/285
A61K 39/23
A61K 39/235
A61K 9/14

US Classification:

424450, 536 2372, 4353201, 435325, 435366, 4241841, 514 44 R, 4242041, 4242111, 435 71, 436 86, 435 792, 4242091, 4242141, 4242321, 4242331, 4242181, 4242311, 424489

Abstract:

The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.

US Patent:

20110091496, Apr 21, 2011

Filed:

Jan 21, 2009

Appl. No.:

12/863572

Inventors:

Barney S. Graham - Rockville MD, US
Christopher B. Buck - Adelphi MD, US
Jeffrey N. Roberts - Rockville MD, US
Teresa R. Johnson - Gaithersburg MD, US
John Nicewonger - Ashburn VA, US
Rhonda Kines - Rockville MD, US
John T. Schiller - Kensington MD, US

International Classification:

A61K 39/12
A61K 39/00
A61K 39/235
A61K 39/155
A61K 39/21
C07H 21/00
C12N 15/63
A61P 31/12
A61P 37/00

US Classification:

4241921, 4241841, 4242041, 4242331, 4242291, 4242111, 4242081, 536 231, 4353201

Abstract:

The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The methods are useful in preventing or treating a subject having a disease or an infection. In particular examples, the methods are useful for preventing or treating a viral infection.

US Patent:

20120315270, Dec 13, 2012

Filed:

Oct 21, 2010

Appl. No.:

13/502595

Inventors:

Jason S. McLellan - Rockville MD, US
Peter D. Kwong - Washington DC, US
Barney S. Graham - Rockville MD, US
William R. Schief - Encinitas CA, US
Joe Jardine - Seattle WA, US
Bruno Correia - San Diego CA, US
Man Chen - Bethesda MD, US

Assignee:

UNIVERSITY OF WASHINGTON - Seattle WA
SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES - Bethesda MD

International Classification:

A61K 39/12
A61K 39/42
A61P 31/14
C07K 16/10
C07K 14/08
C07H 21/04

US Classification:

4241331, 530324, 536 2372, 4241861, 5303873, 536 2353

Abstract:

The present invention provides immunogens that protect against RSV infection. The present invention also provides antibody proteins that protect against RSV infection. Such immunogens and antibody proteins are produced based on three-dimensional models also included in the invention. One model is of a complex between motavizumab and its antibody-binding domain on RSV fusion (F) protein. A second model is of a complex between 10 IF antibody and its antibody-binding domain on RSV F protein. The immunogens disclosed herein have been modified to elicit a humoral response against RSV F protein without eliciting a significant cell-mediated response against RSV. Such immunogens can comprise a scaffold into which RSV contact residues are embedded. The present invention also includes methods that utilize the disclosed three-dimensional models to produce immunogens and antibody proteins of the present invention. Also disclosed are methods of using the disclosed immunogens, for example to protect individuals from RSV infection. Also disclosed are methods of using the disclosed antibody proteins, for example to protect individuals from RSV infection.

US Patent:

20220356229, Nov 10, 2022

Filed:

Mar 4, 2021

Appl. No.:

17/192243

Inventors:

- Vancouver, CA
- Bethesda MD, US
Krithika MUTHURAMAN - Toronto, CA
Kevin JEPSON - Vancouver, CA
Ester FALCONER - Vancouver, CA
John MASCOLA - Bethesda MD, US
Barney GRAHAM - Bethesda MD, US
Kizzmekia CORBETT - Bethesda MD, US
Julie LEDGERWOOD - Bethesda MD, US
Lingshu WANG - Bethesda MD, US
Olubukola ABIONA - Bethesda MD, US
Wei SHI - Bethesda MD, US
Wing-pui KONG - Bethesda MD, US
Yi ZHANG - Bethesda MD, US
Bryan Edward JONES - San Diego CA, US
Denisa FOSTER - San Diego CA, US
Julian DAVIES - La Jolla CA, US
Qing CHAI - San Diego CA, US
Christopher Carl FRYE - Bargersville IN, US
Ganapathy GOPALRATHNAM - Fishers IN, US
Jörg HENDLE - San Diego CA, US
John Michael SAUDER - Carlsbad CA, US
Jeffrey Streetman BOYLES - Indianapolis IN, US
Anna PUSTILNIK - San Diego CA, US

Assignee:

AbCellera Biologics Inc. - Vancouver
The United States of America, as represented by the Secretary, Department of Health and Human Svcs. - Bethesda MD

International Classification:

C07K 16/10
A61K 47/68
G01N 33/569
A61P 31/14

Abstract:

Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

US Patent:

20220339278, Oct 27, 2022

Filed:

May 11, 2022

Appl. No.:

17/742201

Inventors:

- Bethesda MD, US
Barney S. Graham - Smyrna GA, US
John R. Mascola - Rockville MD, US
Hadi M. Yassine - Doha, QA
Kizzmekia S. Corbett - Wheaton MD, US
Syed M. Moin - Laurel MD, US
Lingshu Wang - North Potomac MD, US
Masaru Kanekiyo - Chevy Chase MD, US

Assignee:

The U.S.A., as represented by the Secretary, Department of Health and Human Services - Bethesda MD

International Classification:

A61K 39/145
C07K 14/005
C07K 14/195
A61K 39/12
A61P 31/16

Abstract:

Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.